Last update 26 Dec 2024
Birch pollen allergy vaccine(Anergis)
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Allergen extract |
Synonyms AllerT, AllerT-Birch |
Target- |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with Birch pollen allergy vaccine(Anergis)A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS
A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis
A Double-Blind, Placebo-Controlled, Randomized Trial to Compare the Efficacy and Tolerability of Three Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in Environmental Exposure Chamber
100 Clinical Results associated with Birch pollen allergy vaccine(Anergis)
Login to view more data
100 Translational Medicine associated with Birch pollen allergy vaccine(Anergis)
Login to view more data
100 Patents (Medical) associated with Birch pollen allergy vaccine(Anergis)
Login to view more data
1
Literatures (Medical) associated with Birch pollen allergy vaccine(Anergis)01 Jul 2014The Journal of allergy and clinical immunologyQ1 · MEDICINE
Safety and immunogenicity of immunotherapy with Bet v 1–derived contiguous overlapping peptides
Q1 · MEDICINE
Letter
Author: Audran, Régine ; Thierry, Anne-Christine ; Barbier, Nathalie ; Reymond, Christophe ; Spertini, François ; Charlon, Vincent ; Boudousquié, Caroline ; Pellaton, Céline ; Perrin, Yannick
This article presents the safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides.Clin. trial showed that 5 injections of AllerT administered over 2 mo elicit a strong immune response in the range of that observed after 50 injections and 3 years with other allergens and led to long-term immunol. memory were presented.Changes from baseline in Bet v 1-specific IgG4 and IgE levels were determined, and the ratios of normalized anti-Bet v 1 IgG4 and anti-Bet v 1 IgE over baseline were shown graphically.On an exploratory basis, P values for the median fold difference in IgG4 and IgE levels between AllerT- and placebo-treated patients were determined by using the nonparametric, nonpaired Mann-Whitney test.
100 Deals associated with Birch pollen allergy vaccine(Anergis)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Allergic rhinoconjunctivitis | Phase 2 | CA | 01 Oct 2014 | |
| Rhinitis, Allergic | Phase 2 | CA | 01 Oct 2014 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | DK | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | FR | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | LV | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | LT | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | PL | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | SE | 01 Oct 2012 | |
| Rhinitis, Allergic, Seasonal | Phase 2 | CH | 01 Oct 2012 | |
| Rhinoconjunctivitis | Phase 2 | DK | 01 Oct 2012 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 240 | placebo (Placebo) | ptgovmlier(pnbgpqrmky) = onbbavsijl jtnrdjnxfp (qnzfyqlrmj, hgxqemtgzx - hoxlhpvdjb) View more | - | 13 Apr 2015 | ||
(AllerT Low Dose) | ptgovmlier(pnbgpqrmky) = xzykmxtjhy jtnrdjnxfp (qnzfyqlrmj, otvgyoqjjn - vndudyfwwx) | ||||||
Phase 2 | Anaphylaxis IgG4 | IgE | 239 | 50μg COPs in Aluminum hydroxide | dmisdgvxzx(fhxhzdohpv) = 4 grade 3 systemic allergic reactions (WAO grading) that occurred more than 30 min after injection (total 769 injections of active compound) offqtkzzhe (qklmxqdzwq ) | Positive | 01 Feb 2014 | |
100μg COPs in Aluminum hydroxide |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free